Hansa Biopharma AB
The answer first
Does Hansa Biopharma beat the market?
Yes, Hansa Biopharma has beaten the market over the last year.
The ranking · Quality, value and trend combined
Better than 23% of Nordic stocks
- Quality15
- Value2
- Trend95
No. 122 of 195 in healthcare
Expectations in the price
Low expectations
For the share to return about 9% a year from today's price, it is enough that the cash Hansa Biopharma keeps shrinks about 4% a year for 10 years.
Max for seven days
Follow Hansa Biopharma with AuroraAurora lets you know at the next report. No card.
Both with dividends. Figures as of 19 November 2026. General analysis, not personal advice.
Follow your thesis
Ask Aurora about Hansa Biopharma
Your first answer is free, no account needed.
Do you own Hansa Biopharma, or are you thinking about it?
See it next to the rest of your portfolio, or build your first one with Hansa Biopharma and a few more. Free, no card.
Super Stock+46.4%In short
- Hansa Biopharma has risen 74.2% over the past year, including dividends.
- Overall, Hansa Biopharma ranks better than 23% of Nordic stocks on quality, value and trend.
- The largest fall over the past three years was 90.6%. The price is 86.4% below its peak now.
What do analysts think of Hansa Biopharma?
Quality, value and trend
Quality is about the company, value about the price you pay, and trend about the share price. Each pillar shows the numbers it is built on.
Quality, value and trend together. Better than 23% of Nordic stocks.
No. 122 of 195 in healthcare
Low Weaker accounts than most: low profitability, high debt or uneven results.
No. 179 of 196 in healthcareTypical in healthcare: 64Typical in the Nordics: 50
- Debt to equityBorrowings divided by equity−1.45
- Asset turnoverSales divided by everything the company owns0.16
- Return on equityProfit divided by equity−116.8%
- Cash conversionOperating cash flow divided by profit–
The ranking is built on equity ratio, ROA and how steadily profit grows.
Low High price: buyers pay a lot today, often because they expect growth.
No. 185 of 197 in healthcareTypical in healthcare: 20Typical in the Nordics: 50
- P/BPrice divided by equitynegative earnings
- P/SPrice divided by sales15.4
- P/EPrice divided by earningsnegative earnings
- P/CFPrice divided by operating cash flow8.8
The ranking is built on P/E, P/B and P/S.
High Tailwind in the share price: it has risen more than most over the last year.
No. 13 of 198 in healthcareTypical in healthcare: 34Typical in the Nordics: 50
- 3 months+13.1%
- 6 months+40.8%
- 9 months+46.9%
- 12 months+74.2%
The ranking is built on 3, 6 and 12–1 months.
Return and risk
Return with dividends reinvested.
The funds that own Hansa Biopharma
12 funds we follow own Hansa Biopharma. The share is how much of the fund the stock makes up.
- Norway1
- Sweden11
- Avanza Impact by CirculusSweden · Avanza1.9%
- PLUS Hälsovård Sverige IndexSweden · PLUS1.0%
- HealthInvest Small & MicroCap Fund CSweden · HealthInvest0.7%
- HealthInvest Small & Mid Cap Healthcare ESweden · HealthInvest0.7%
- Handelsbanken Norden Ind Crit (A1 NOK)Sweden · Handelsbanken0.2%
- Skandia Småbolag Sverige Exponering ASweden · Skandia0.1%
- PLUS Småbolag Sverige IndexSweden · PLUS0.1%
- PLUS Allabolag Sverige IndexSweden · PLUS0.0%
From the funds' latest known holdings.
About Hansa Biopharma
Hansa Biopharma AB is a company in healthcare, listed on Nasdaq Stockholm. The share trades in SEK. It has around 120 employees.
Hansa Biopharma AB (publ), a biopharmaceutical company, engages in development and commercialization of treatments for patients with rare immunological conditions in Sweden, North America, and rest of Europe. The company offers Idefirix(imlifidase), which targets and cleaves all classes of immunoglobulin G (IgG) antibodies for the desensitization treatment of sensitized adult kidney transplant patients with a positive crossmatch test. It also develops HNSA-5487, a next generation IgG-cleaving enzyme to address acute and chronic neuro-autoimmune conditions, including myasthenia gravis.


See the full analysis of Hansa Biopharma.
The accounts, dividends, 40 years of charts and the comparison with other stocks are in the app.
Free forever · No card